Dr. Reddys Laboratories announced that it has entered into a licensing agreement with Eisai Co. Ltd, Japan by which Dr. Reddys will be granted exclusive worldwide development and commercialisation rights (excluding Japan and Asia) for Eisais investigational anti-cancer agent E7777. Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr. Reddys holds the option for rights to develop and market the agent in India.
In exchange of these rights, Eisai will receive milestone payments in line with obtaining marketing approval and the achievement of agreed upon sales targets. Through this agreement, the two companies aim to accelerate development and maximize the value of E7777.
Raghav Chari, utive Vice President, Proprietary Products Group, Dr. Reddys Laboratories, said The collaboration between DRL and Eisai is a tremendous win-win. E7777 has significant potential as an important component of systemic therapy for Cutaneous T-Cell Lymphoma (CTCL). This therapy represents an extension of our current efforts in the dermatology space to an important segment of skin-related cancers.
Terushige Iike, Chief Product Creation Officer of Eisai Product Creation Systems, said This agreement aligns with Eisais drive to contribute to patients in our focused field of oncology as quickly as possible. Eisai and Dr. Reddys will conduct development in their respective territories, and by working to accelerate and maximise contribution to patients, we hope to launch treatments that will fulfill the diverse needs of and bring about benefits for patients with cancer and their families.